Harpoon Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HARP research report →
About the company
Harpoon Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to immunotherapy, focused on engineering a novel class of T cell activators. These therapies are designed to leverage the body's own immune system to fight cancer and other diseases in patients across the United States.
- CEO
- Julie M. Eastland
- IPO
- 2019
- Employees
- 45
- HQ
- South San Francisco, CA, US
Price Chart
- Market Cap
- $865.08M
- P/E
- -1.14
- P/S
- 27.11
- P/B
- 14.14
- EV/EBITDA
- -12.57
- Div Yield
- 0.00%
- Gross Margin
- 90.30%
- Op Margin
- -214.08%
- Net Margin
- -210.36%
- ROE
- -211.56%
- ROIC
- -285.53%
- Revenue
- $31.91M · 34.92%
- Net Income
- $-67,137,000 · 59.66%
- EPS
- $-20.24 · 60.75%
- Op Income
- $-68,325,000
- FCF YoY
- 26.77%
- 52W High
- $23.21
- 52W Low
- $3.11
- 50D MA
- $20.73
- 200D MA
- $10.76
- Beta
- 1.55
- Avg Volume
- 1.13M
Get TickerSpark's AI analysis on HARP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 11, 24 | New Leaf Biopharma Opportunities II, L.P. | sell | 299,430 |
| Mar 11, 24 | New Leaf Biopharma Opportunities II, L.P. | sell | 395,783 |
| Mar 11, 24 | New Leaf Biopharma Opportunities II, L.P. | sell | 10,000 |
| Mar 11, 24 | New Leaf Biopharma Opportunities II, L.P. | sell | 85,750 |
| Mar 11, 24 | SILVERNAIL LAUREN P | sell | 5,000 |
| Mar 11, 24 | SILVERNAIL LAUREN P | sell | 2,033 |
| Mar 11, 24 | SILVERNAIL LAUREN P | sell | 2,300 |
| Mar 8, 24 | HUNT RONALD | other | 424 |
| Mar 11, 24 | HUNT RONALD | sell | 10,000 |
| Mar 11, 24 | HUNT RONALD | sell | 299,430 |
Our HARP coverage
Recent articles, reports, and earnings notes.
No research on HARP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HARP report →Similar companies
Peers in the same neighborhood.